SEC Filing | Amicus Therapeutics

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

FHM IV LP

(Last)

(First)

(Middle)

TWO UNION SQUARE

601 UNION STREET STE 3200

(Street)

SEATTLE

98101

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/30/2007

3. Issuer Name and Ticker or Trading Symbol
AMICUS THERAPEUTICS INC [ FOLD ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series B Convertible Preferred Stock	⁽¹⁾	⁽¹⁾	Common Stock	988,446	⁽¹⁾	I⁽²⁾	By Frazier Healthcare IV, LP
Series B Convertible Preferred Stock	⁽¹⁾	⁽¹⁾	Common Stock	5,016	⁽¹⁾	I⁽²⁾	By Frazier Affiliates IV, LP
Series C Convertible Preferred stock	⁽¹⁾	⁽¹⁾	Common Stock	1,011,088	⁽¹⁾	I⁽²⁾	By Frazier Healthcare IV, LP
Series C Convertible Preferred Stock	⁽¹⁾	⁽¹⁾	Common Stock	5,132	⁽¹⁾	I⁽²⁾	By Frazier Affiliates IV, LP
Series D Convertible Preferred Stock	⁽¹⁾	⁽¹⁾	Common Stock	572,310	⁽¹⁾	I⁽²⁾	By Frazier Healthcare IV, LP
Series D Convertible Preferred stock	⁽¹⁾	⁽¹⁾	Common Stock	2,904	⁽¹⁾	I⁽²⁾	By Frazier Affiliates IV, LP
Warrant to purchase Series B (right to buy)	⁽³⁾	⁽³⁾	Series B Convertible Preferred Stock	15,042	6.375	I⁽²⁾	By Frazier Healthcare IV, LP
Warrant to purchase Series B (right to buy)	⁽³⁾	⁽³⁾	Series B Convertible Preferred Stock	76	6.375	I⁽²⁾	By Frazier Affiliates IV, LP

1. Name and Address of Reporting Person^*

FHM IV LP

(Last)

(First)

(Middle)

TWO UNION SQUARE

601 UNION STREET STE 3200

(Street)

SEATTLE

98101

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

FRAZIER HEALTHCARE IV LP

(Last)

(First)

(Middle)

(Street)

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

FRAZIER AFFILIATES IV LP

(Last)

(First)

(Middle)

(Street)

(City)

(State)

(Zip)

Explanation of Responses:

1. The Issuer's Series B, Series C and Series D convertible preferred stock will automatically be converted into Common Stock, 1-for-1, upon the closing of the Issuer's initial public offering.

2. These securities are owned directly by the entity listed. Frazier Healthcare IV, LP and Frazier Affiliates IV, LP, are joint filers. FHM IV, LP, the designated filer, serves as the general partner of Frazier Healthcare IV, LP and Frazier Affiliates IV, LP. FHM IV, LP disclaims beneficial ownership of the reported securities, except to the extent of its proportionate pecuniary interest therein.

3. Warrant to purchase Series B convertible preferred stock will automatically be exercised for cash immediately prior to the closing of the Issuer's initial public offering. The Series B shares will automatically be converted to Common Stock upon the closing of the initial public offering.

Remarks:

Exhibit 99.1 Joint Filer Information

	FHM IV, LP By: FHM IV, LLC, its General Partner /s/ Thomas S. Hodge, Chief Operating Officer	05/30/2007
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Exhibit 99.1

Form 3 Joint Filer Information

Name:

Frazier Healthcare IV, LP

Address:	601 Union Street, Suite 3200, Seattle, WA 98101

Designated Filer:	FHM IV, LP

Issuer & Ticker Symbol:

Amicus Therapeutics, Inc. (FOLD)

Date of Event Requiring Statement:

May 30, 2007

Frazier Healthcare IV, LP

By: FHM IV, LP, its General Partner

	By: FHM IV, LLC, its General Partner

	By:	/s/ Thomas S. Hodge

Thomas S. Hodge, Chief Operating Officer

Name:

Frazier Affiliates IV, LP

Address:	601 Union Street, Suite 3200, Seattle, WA 98101

Designated Filer:	FHM IV, LP

Issuer & Ticker Symbol:

Amicus Therapeutics, Inc. (FOLD)

Date of Event Requiring Statement:

May 30, 2007

Frazier Affiliates IV, LP

By: FHM IV, LP, its General Partner

	By: FHM IV, LLC, its General Partner

	By:	/s/ Thomas S. Hodge

Thomas S. Hodge, Chief Operating Officer